Background: Direct oral anticoagulants (DOACs) are widely used as therapies for venous thromboembolism and other cardiovascular diseases. However, routine coagulation monitoring is not required, but may be clinically indicated in high risk populations including obese patients.
Objectives: The aims of this study were two fold; to validate a chromogenic assay for anti-factor Xa measurement in patients taking apixaban, and correlate it with PT/INR and PTT, and to measure anti-factor Xa levels in patients who weighed >120 kg.
Patients/methods: Patients who were taking apixaban had 3 blood samples drawn over a 4 h period. Apixaban levels were determined using an anti-factor Xa activity assay (STA-Liquid Anti-Xa) using STA-Apixaban Calibrator and STA-Apixaban Controls. The PT/INR was determined using standard methodology. Apix MS, using manufacturer provided apixaban standard, was performed on plasma.
Results And Conclusions: 18 normal weight patients, 39 obese patients and 14 controls were enrolled. There was a strong correlation between apixaban anti-factor Xa activity compared to plasma Apix MS (r = 0.95). In patients >120 kg, there was a statistically significant decreased rate of change in anti-factor Xa levels after ingestion. Further, the area under the curve for apixaban anti-factor Xa levels was significantly lower in patients over 120 kg. While INR correlated with apixaban MS and apixaban anti-factor Xa activity in both normal weight and obese patients, the association was not sufficiently strong to clinically manage patients, normal weight or obese. Given these findings, research is necessary to investigate the clinical utility of apixaban anti-factor Xa activity measurement in selected populations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2019.08.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Anticoagulation Reversal in Intracerebral Hemorrhage: A Case Report on the Efficacy of Andexanet Alfa in an Apixaban-Treated Patient.
Cureus
November 2024
Neurosurgery, County Clinical Emergency Hospital of Sibiu, Sibiu, ROU.
Intracerebral hemorrhage (ICH) presents complex clinical challenges, particularly in patients receiving anticoagulation therapy. This case report discusses the management of acute ICH in a 60-year-old male patient on long-term apixaban therapy, who arrived at the emergency department with altered consciousness, right-sided hemiplegia, and mixed aphasia. Computed tomography (CT) imaging revealed a 70 ml left lenticular-capsular hematoma with significant mass effect, necessitating rapid intervention.
View Article and Find Full Text PDFMonitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors.
Sci Rep
October 2024
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Article Synopsis
- Direct oral anticoagulants (DOACs), particularly factor Xa (FXa) inhibitors, are used in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after venous thromboembolism, though data on their effects are limited.
- A study involving 50 CTEPH patients analyzed the anti-factor Xa activity (AXA) of different FXa inhibitors (rivaroxaban, apixaban, edoxaban) and found that apixaban had significantly higher trough AXA levels compared to rivaroxaban and edoxaban.
- Higher peak AXA levels (≥2.09 IU/mL) were associated with an increased risk of major bleeding, indicating that monitoring
Background: The first purpose of this study was to determine whether a measurement of the level of direct oral anticoagulants (DOACs) was possible with heparin-calibrated chromogenic anti-factor Xa activity (AXA). The second purpose of this study was to evaluate whether the antidote treatment decision level (30 or 50 ng/mL of DOAC) can be determined by unfractionated heparin (UHF)/low molecular weight heparin (LMWH)-calibrated AXA.
Methods: AXA was measured by using two reagents and dedicated analyzers (Sysmex CS-5100 analyzer and STA R Max3).
Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review.
Rev Cardiovasc Med
October 2023
Cardio-Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II", 70124 Bari, Italy.
Cancer-associated thrombosis (CAT) is a devastating complication of cancer that can significantly impact a patient's health and life. The incidence of CAT is approximately 20%, and 1 in 5 cancer patients will develop CAT annually. Indeed, CAT can promote pulmonary embolism and deep vein thrombosis, leading to increased morbidity and mortality that dramatically impact survival.
View Article and Find Full Text PDFIs anticoagulative therapy in systemic sclerosis to be reconsidered?
J Scleroderma Relat Disord
June 2024
Department of Medical Sciences and Public Health, Hemostasis and Thrombosis Unit, University of Cagliari and AOU of Cagliari, Cagliari, Italy.
Article Synopsis
- - Systemic sclerosis is a rare and serious autoimmune disease characterized by vascular and tissue fibrosis, leading to complications like increased clotting and pulmonary hypertension.
- - The condition triggers endothelial damage, causing immune and platelet activation, which contributes to blood clot formation and potential vascular obstruction.
- - Research is ongoing for new anticoagulant treatments, including anti-factor XI drugs and various molecular types, aimed at improving patient outcomes and minimizing bleeding risks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!